Satellos Bioscience (MSLE)
Developing SAT-3247, an oral muscle-repair therapy for Duchenne muscular dystrophy.
Something off on this page? Send us feedback.
Develops the investigational oral AAK1 inhibitor SAT-3247 for Duchenne muscular dystrophy and uses the MyoReGenX ex-vivo platform to assess potential therapies for degenerative muscle diseases. Potential monetization includes biopharmaceutical partnerships, self-directed commercialization, or M&A; the single-candidate program has no product revenue.
Develops SAT-3247, an investigational oral small-molecule AAK1 inhibitor designed to restore muscle-stem-cell repair signaling in Duchenne muscular dystrophy without replacing dystrophin. Uses the MyoReGenX ex-vivo screening platform to model the muscle-stem-cell environment and assess targets and compounds for DMD and other degenerative muscle diseases.
Operates across Canada, the United States, and Australia, with clinical studies extending through North America, Europe, the United Kingdom, and other regions.
Runs one operating segment focused on researching small-molecule drug candidates and keeps a small internal team for preclinical development, chemistry, manufacturing, and controls, and clinical development while supervising specialized CROs. Has earned no revenue; potential monetization includes biopharmaceutical partnerships, self-directed commercialization, or M&A. Clinical progress depends on trial and regulatory outcomes, external funding, a single contract manufacturer, and an exclusive, royalty-bearing license with the Ottawa Hospital Research Institute.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $61.8M · Total debt $0 · Total assets $65.7M · Shareholders' equity $59.8M
- Revenue
- $0
- Operating income
- −$11.9M
- Net income
- −$11.4M
No dividends on record.
| Institutions | 596.51% | 7.68M shares | |
|---|---|---|---|
| 26 holders · as of Jun 30, 2026 | |||
| Adds to | 596.51% | ||
1.29M company shares as of Sep 10, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 596.51%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Franklin Resources IncInstitution | 72.86% | 938,666 | as of Jun 30, 2026 |
Siren, L.L.C.Institution | 69.25% | 892,074 | as of Jun 30, 2026 |
Vivo Capital, LLCInstitution | 63.16% | 813,666 | as of Jun 30, 2026 |
Point72 Asset Management, L.P.Institution | 52.99% | 682,700 | as of Jun 30, 2026 |
Sphera Funds Management Ltd.Institution | 50.66% | 652,590 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Sarepta Therapeutics
Broad DMD threat across gene therapy and exon-skipping.
- PTC Therapeutics
Established all-variant corticosteroid therapy in DMD care.
- REGENXBIO
Late-stage microdystrophin gene therapy for broad DMD use.
- Dyne Therapeutics
Near-registration exon-51 therapy for DMD muscle function.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Satellos Bioscience | $9.02 | +0.20% | $11.8M | — | — | — | — |
| Sarepta Therapeutics | $20.86 | +0.19% | $2.13B | — | 36.2 | 1.1 | −34.3% |
| PTC Therapeutics | $65.96 | +0.02% | $5.45B | — | 53.3 | 5.4 | +101.6% |
| REGENXBIO | $8.15 | −0.12% | $407.4M | — | — | 2.3 | +405.7% |
| Dyne Therapeutics | $17.20 | +0.35% | $3.20B | — | — | — | — |
| Median | — | 44.8 | 2.3 | +101.6% |